Decision-ready evidence, accelerated.
Comparative evidence for multiple markets.
We generate the HTA-grade comparative evidence that maximises a drug's value, in weeks not months.
THE SITUATION
Your drug has never been compared directly against an existing treatment.
Your pivotal evidence comes from a single-arm trial. Or you have randomised data but not against an existing treatment that payers already fund.
HTA bodies, payers, and clinical teams all want the same answer: how does your drug compare to what patients already receive?
That answer must come from evidence outside your trial. And it has to hold up to external scrutiny.
WHY NOW
Comparative evidence is now mandatory in Europe and the US.
EU Joint Clinical Assessment
Developers have 100 days to submit evidence on how their drug compares with existing treatments in 27 countries.
US Inflation Reduction Act
Selected developers have 30 days to submit comparative evidence to CMS for Medicare price negotiation.
The EU timeline
Oncology and advanced therapies from 2025. Orphan medicines from 2028. All new medicines from 2030.
THE SOLUTION
Evidax builds the missing comparative evidence from outside the trial, in weeks.
-
Step 1. PLAN
Evidax IEP Method
A six-step method that identifies the evidence gaps gating market access and builds an Integrated Evidence Plan to close them.
-
Step 2. SYNTHESISE
Evidax TRACE
An AI-augmented platform that synthesises the entire published literature and real-world data, identifying every comparison that can be built.
-
Step 3. GENERATE
Evidax Comparison Blueprints
HTA-grade workflows for indirect comparisons and external control arms, built by leading methodologists.
Evidax in numbers
- 20 days
- Integrated Evidence Plan
- 14 days
- Systematic review and meta-analysis
- 10 days
- Indirect treatment comparison
- 15 years
- Leading clinical research programmes
WHY US
Most firms are either rigorous or fast. Evidax is both.
Large HEOR firms
These produce evidence that holds up. Bureaucracy means they take months, and the launch window does not wait.
Boutique HEOR firms
These are smaller and faster, and senior people do the work. Every comparison is still built by hand, so multiple markets means multiple projects.
AI platforms
These are fast. Their workflows are not built to survive an HTA committee, and none of them puts a named person behind the output.
Your streamlined evidence plan, live and in one place
The Evidax Workspace keeps your whole team aligned as the plan evolves and new evidence is generated.
Leadership team
Dr Sam Orange
Founder & Chief Scientific Officer
Professor Ian Hickson
Senior Scientific Adviser: Drug discovery
Dr Tom Maden-Wilkinson
Senior Scientific Advisor: Biotech strategy
Professor James Wason
Senior Scientific Advisor: Biostatistics
Ben Porter
Senior Scientific Advisor: RWE and evidence synthesis